The US Patent Office has granted US patent 13/923,577 to Graftys, covering GRFT-R02—an osteogenic biomaterial for bone tissue regeneration.
This is the 8th patent granted to the company or to its licensors. It results from a large collaboration between Graftys and the University of Nice and the Laboratory of CNRS UMR 6235 (both Nice, France). Based on the priority date, the patent protection should last until 2028.
Jean-Marc Ferrier, Graftys vice president of Business Development, comments, “GRFT-R02 is a unique and highly osteogenic putty. This biomaterial is expected to allow surgeons to address difficult surgical situations like…spinal fusion, non-union and complex cases of fracture healing with poor vascularisation. GRFT-R02 showed…osteoinductive properties in preclinical models with enhanced bone regeneration, and was able to repair critical segmental bone defects in animal models. This biomaterial has…demonstrated similar efficacy to autograft…in preclinical studies and is expected to exhibit a better safety profile compared to bone morphogenetic protein-derived products”.
About GRFT-R02 GRFT-R02 is an osteogenic putty based on a combination of autologous whole blood and ceramic, with optimised handling characteristics. According to the release, the ceramic contains biphasic calcium phosphate particles calibrated to optimise osteoconduction, and enriched with calcium ions to enhance clot formation. The formation of fibrin has demonstrated increased biologic and osteogenic activity in preclinical studies. Targeted clinical indications include large bone defects (acetabular reconstruction, osteotomies), non-union and posterolateral spinal fusion.